296 related articles for article (PubMed ID: 18632614)
1. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice.
Daikoku T; Hirota Y; Tranguch S; Joshi AR; DeMayo FJ; Lydon JP; Ellenson LH; Dey SK
Cancer Res; 2008 Jul; 68(14):5619-27. PubMed ID: 18632614
[TBL] [Abstract][Full Text] [Related]
2. The uterine epithelial loss of Pten is inefficient to induce endometrial cancer with intact stromal Pten.
Liang X; Daikoku T; Terakawa J; Ogawa Y; Joshi AR; Ellenson LH; Sun X; Dey SK
PLoS Genet; 2018 Aug; 14(8):e1007630. PubMed ID: 30142194
[TBL] [Abstract][Full Text] [Related]
3. Cell-specific conditional deletion of Pten in the uterus results in differential phenotypes.
Daikoku T; Jackson L; Besnard V; Whitsett J; Ellenson LH; Dey SK
Gynecol Oncol; 2011 Aug; 122(2):424-9. PubMed ID: 21570712
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus mediated homozygous endometrial epithelial Pten deletion results in aggressive endometrial carcinoma.
Joshi A; Ellenson LH
Exp Cell Res; 2011 Jul; 317(11):1580-9. PubMed ID: 21397598
[TBL] [Abstract][Full Text] [Related]
5. Conditional abrogation of transforming growth factor-β receptor 1 in PTEN-inactivated endometrium promotes endometrial cancer progression in mice.
Gao Y; Lin P; Lydon JP; Li Q
J Pathol; 2017 Sep; 243(1):89-99. PubMed ID: 28657664
[TBL] [Abstract][Full Text] [Related]
6. Mutual contribution of Pten and estrogen to endometrial carcinogenesis in a PtenloxP/loxP mouse model.
Saito F; Tashiro H; To Y; Ohtake H; Ohba T; Suzuki A; Katabuchi H
Int J Gynecol Cancer; 2011 Nov; 21(8):1343-9. PubMed ID: 21989218
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.
Koivisto CS; Parrish M; Bonala SB; Ngoi S; Torres A; Gallagher J; Sanchez-Hodge R; Zeinner V; Nahhas GJ; Liu B; Cohn DE; Backes FJ; Goodfellow PJ; Chamberlin HM; Leone G
Neoplasia; 2020 Oct; 22(10):484-496. PubMed ID: 32818842
[TBL] [Abstract][Full Text] [Related]
8. Pten and Dicer1 loss in the mouse uterus causes poorly differentiated endometrial adenocarcinoma.
Wang X; Wendel JRH; Emerson RE; Broaddus RR; Creighton CJ; Rusch DB; Buechlein A; DeMayo FJ; Lydon JP; Hawkins SM
Oncogene; 2020 Oct; 39(40):6286-6299. PubMed ID: 32843721
[TBL] [Abstract][Full Text] [Related]
9. Endometrial tumorigenesis in Pten(+/-) mice is independent of coexistence of estrogen and estrogen receptor α.
Joshi A; Wang H; Jiang G; Douglas W; Chan JS; Korach KS; Ellenson LH
Am J Pathol; 2012 Jun; 180(6):2536-47. PubMed ID: 22503752
[TBL] [Abstract][Full Text] [Related]
10. An inducible knockout mouse to model the cell-autonomous role of PTEN in initiating endometrial, prostate and thyroid neoplasias.
Mirantes C; Eritja N; Dosil MA; Santacana M; Pallares J; Gatius S; Bergadà L; Maiques O; Matias-Guiu X; Dolcet X
Dis Model Mech; 2013 May; 6(3):710-20. PubMed ID: 23471917
[TBL] [Abstract][Full Text] [Related]
11. Elevation of ω-3 Polyunsaturated Fatty Acids Attenuates PTEN-deficiency Induced Endometrial Cancer Development through Regulation of COX-2 and PGE2 Production.
Pan J; Cheng L; Bi X; Zhang X; Liu S; Bai X; Li F; Zhao AZ
Sci Rep; 2015 Oct; 5():14958. PubMed ID: 26468779
[TBL] [Abstract][Full Text] [Related]
12. The synergistic effect of Mig-6 and Pten ablation on endometrial cancer development and progression.
Kim TH; Franco HL; Jung SY; Qin J; Broaddus RR; Lydon JP; Jeong JW
Oncogene; 2010 Jul; 29(26):3770-80. PubMed ID: 20418913
[TBL] [Abstract][Full Text] [Related]
13. In Vivo Intra-Uterine Delivery of TAT-Fused Cre Recombinase and CRISPR/Cas9 Editing System in Mice Unveil Histopathology of Pten/p53-Deficient Endometrial Cancers.
Navaridas R; Vidal-Sabanés M; Ruiz-Mitjana A; Altés G; Perramon-Güell A; Yeramian A; Egea J; Encinas M; Gatius S; Matias-Guiu X; Dolcet X
Adv Sci (Weinh); 2023 Nov; 10(32):e2303134. PubMed ID: 37749866
[TBL] [Abstract][Full Text] [Related]
14. Mig-6 suppresses endometrial cancer associated with Pten deficiency and ERK activation.
Kim TH; Yoo JY; Kim HI; Gilbert J; Ku BJ; Li J; Mills GB; Broaddus RR; Lydon JP; Lim JM; Yoon HG; Jeong JW
Cancer Res; 2014 Dec; 74(24):7371-82. PubMed ID: 25377472
[TBL] [Abstract][Full Text] [Related]
15. [Immunomorphologic features of epithelial-stromal relationships at hyperplasia and endometrial carcinoma].
Bantysh BB; Paukov vS; Kogan EA
Arkh Patol; 2012; 74(3):22-5. PubMed ID: 22937575
[TBL] [Abstract][Full Text] [Related]
16. Akt regulates COX-2 mRNA and protein expression in mutated-PTEN human endometrial cancer cells.
St-Germain ME; Gagnon V; Mathieu I; Parent S; Asselin E
Int J Oncol; 2004 May; 24(5):1311-24. PubMed ID: 15067356
[TBL] [Abstract][Full Text] [Related]
17. LncRNA-GAS5 induces PTEN expression through inhibiting miR-103 in endometrial cancer cells.
Guo C; Song WQ; Sun P; Jin L; Dai HY
J Biomed Sci; 2015 Oct; 22():100. PubMed ID: 26511107
[TBL] [Abstract][Full Text] [Related]
18. Neonatal estrogenic exposure suppresses PTEN-related endometrial carcinogenesis in recombinant mice.
Begum M; Tashiro H; Katabuchi H; Suzuki A; Kurman RJ; Okamura H
Lab Invest; 2006 Mar; 86(3):286-96. PubMed ID: 16402032
[TBL] [Abstract][Full Text] [Related]
19. Gene expression analysis reveals a signature of estrogen receptor activation upon loss of Pten in a mouse model of endometrial cancer.
Lian Z; De Luca P; Di Cristofano A
J Cell Physiol; 2006 Aug; 208(2):255-66. PubMed ID: 16688764
[TBL] [Abstract][Full Text] [Related]
20. Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus.
Lindberg ME; Stodden GR; King ML; MacLean JA; Mann JL; DeMayo FJ; Lydon JP; Hayashi K
Biol Reprod; 2013 Jul; 89(1):8. PubMed ID: 23740945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
